Yes. In the United States, an eligible patient can switch from intravenous Leqembi to the Leqembi IQLIK subcutaneous autoinjector during either the initial treatment period or maintenance treatment. For example, a patient completing 18 months of IV infusions may move to a 360-milligram injection once a week, with the first subcutaneous dose given one week after the last IV dose. The switch must be prescribed and supervised by the treating clinician; it is not simply a matter of replacing the next infusion with an injection at home. At-home treatment also does not begin without training.
Current prescribing information calls for a healthcare provider to give direct guidance for at least two consecutive subcutaneous doses before deciding that the patient or caregiver can administer the drug safely. The patient still needs scheduled brain MRIs, monitoring for amyloid-related imaging abnormalities, or ARIA, and prompt evaluation of concerning symptoms. The FDA-approved subcutaneous starting regimen expands the option beyond maintenance treatment, although the manufacturer has said the 500-milligram starting dose is planned for a U.S. launch in late August 2026, so local availability may lag behind approval. FDA.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Can Alzheimer’s Patients Switch From IV Leqembi to At-Home Injections?
- Leqembi IQLIK Starting and Maintenance Doses
- Safety Monitoring Does Not Move Home
- How to Plan the Switch With the Care Team
- Common Problems With At-Home Leqembi Injections
- Blood Thinners, APOE Status, and Individual Risk
- Missed Doses and Changes Back to IV Treatment
- Frequently Asked Questions
Can Alzheimer’s Patients Switch From IV Leqembi to At-Home Injections?
Patients may switch routes while receiving the starting regimen or while receiving maintenance treatment. During the first 18 months, the IV regimen is 10 milligrams per kilogram once every two weeks, while the subcutaneous starting regimen is 500 milligrams once a week, delivered as two 250-milligram injections. If a patient switches from IV treatment to subcutaneous treatment during this period, the first subcutaneous dose is scheduled one week after the last infusion. After 18 months, the choices broaden. A patient may continue the starting regimen, move to IV maintenance treatment once every four weeks, or use a 360-milligram subcutaneous injection once a week.
A patient switching from IV to subcutaneous maintenance also receives the first injection one week after the last IV dose. This is a route and schedule change, not a discontinuation of lecanemab therapy. Leqembi prescribing information Approval does not mean that every person with Alzheimer’s disease is an appropriate candidate. Leqembi was studied and should be initiated in people with mild cognitive impairment or mild dementia due to Alzheimer’s disease, with amyloid pathology confirmed before treatment. Someone with moderate or severe dementia should not assume that the autoinjector makes Leqembi appropriate, because those later stages were not the population in which treatment was initiated in the pivotal trials.
Leqembi IQLIK Starting and Maintenance Doses
The injection schedule depends on where the patient is in treatment. The subcutaneous starting dose is 500 milligrams weekly, requiring two separate 250-milligram autoinjectors. The maintenance dose is 360 milligrams weekly and uses one 360-milligram autoinjector. A family should verify the strength, number of devices, and treatment phase whenever a new shipment arrives; using one 250-milligram device when two were prescribed would deliver only half of the starting dose. IV Leqembi is weight-based and administered over approximately one hour in a clinical setting. Leqembi iqlik is a fixed-dose injection under the skin. The home option eliminates IV placement and routine infusion-center travel, but it changes the schedule from every two weeks to every week during initial treatment.
During maintenance, a family may be comparing one at-home injection each week with one clinic infusion every four weeks, rather than comparing treatments given at the same frequency. There is an important evidence limitation. The original large clinical outcome trials evaluated IV lecanemab at 10 milligrams per kilogram every two weeks. The subcutaneous formulation was not tested in a separate large, placebo-controlled trial designed to prove a cognitive benefit on its own. FDA approval relied on the established IV evidence together with findings that subcutaneous dosing produced equivalent drug exposure and similar amyloid-plaque reduction. Families should understand this distinction when a clinician describes the formulations as therapeutic alternatives. FDA.
Safety Monitoring Does Not Move Home
Changing the delivery method does not remove Leqembi’s boxed warning for ARIA. ARIA can involve temporary brain swelling, small areas of bleeding, or deposits from prior bleeding. It is often found on MRI before symptoms appear, but it can occasionally become serious, life-threatening, or fatal. Headache, confusion, dizziness, nausea, vision changes, difficulty walking, seizures, or a new focal neurological problem require prompt medical attention. A baseline brain MRI is needed before treatment.
Current labeling also calls for MRIs after approximately one, two, three, and six months of treatment, usually close enough to the next dose that the clinician can review the scan before treatment proceeds. Switching to home injections does not restart or erase this monitoring schedule. Additional imaging may be needed if symptoms develop or an earlier scan shows ARIA. For example, if a person using the autoinjector suddenly develops facial weakness and trouble speaking, the caregiver should seek emergency care rather than waiting for the neurology office to return a routine call. ARIA can sometimes resemble an ischemic stroke, and emergency clinicians need to know that the patient is receiving an amyloid-targeting antibody before considering clot-dissolving treatment. Keeping an updated medication list or treatment card with the patient can provide that information when memory or speech is impaired.
How to Plan the Switch With the Care Team
The decision should begin with the clinician reviewing the patient’s treatment phase, MRI findings, previous infusion reactions, other medications, and ability to follow a weekly schedule. The prescriber should specify the date of the last IV infusion, the date and strength of the first injection, and whether the patient is remaining on a starting regimen or moving to maintenance. A written calendar is safer than relying on the patient to calculate the interval. At least two consecutive subcutaneous doses must be given with direct guidance from a healthcare provider before home administration is considered appropriate. Training should cover device handling, injection technique, allergic-reaction symptoms, missed doses, storage, and disposal.
A person with mild dementia may operate an autoinjector successfully during training but later forget whether a dose was taken, making caregiver administration or direct observation the safer arrangement. The tradeoff is convenience versus responsibility. An infusion center handles storage, dose preparation, administration, and immediate observation. At home, the patient and caregiver gain freedom from frequent clinic visits but assume responsibility for refrigeration, weekly scheduling, correct device selection, skin inspection, and recognition of adverse reactions. For someone living far from an infusion center, that trade may be worthwhile; for someone who lives alone and has unreliable medication routines, monthly IV maintenance may provide a safer structure.
Common Problems With At-Home Leqembi Injections
Injection-related reactions can include redness, swelling, rash, pain, or bruising. Approved sites include the abdomen and front of the thighs; a healthcare provider or caregiver may also use the back of the upper arm. Injection locations should be rotated, with each dose placed at least one inch from the previous site. The device should not be used on bruised, scarred, tattooed, tender, hard, red, or injured skin, or within two inches of the navel. Storage errors are another concern. Autoinjectors should ordinarily be refrigerated at 36°F to 46°F and kept in their original packaging to protect them from light.
Before use, the device should sit at room temperature for 20 minutes without an external heat source. It must not be shaken, frozen, dropped, or used if the solution is cloudy or contains visible particles. A device brought to room temperature may remain in its original package at temperatures up to 77°F for as long as 14 days, but it should not be returned to the refrigerator. Serious allergic reactions are possible even when earlier doses were tolerated. Swelling of the face, lips, mouth, or tongue, hives, or trouble breathing calls for emergency help. The clinician must consider whether the patient or caregiver can recognize and manage these symptoms before approving home administration. A caregiver who visits only once a week may also need a plan for observing the patient immediately after the injection and confirming that no device or dose was missed.
Blood Thinners, APOE Status, and Individual Risk
Testing for APOE ε4 status should be performed before Leqembi is initiated because people with two copies of the APOE ε4 variant have a higher incidence of ARIA, including symptomatic and serious cases. Switching from IV to injection does not alter that genetic risk. A patient’s history of brain microbleeds, superficial siderosis, or other findings suggestive of cerebral amyloid angiopathy also matters when the clinician weighs continued treatment.
Anticoagulants require particular caution because their use was associated with more intracerebral hemorrhages among Leqembi-treated patients than among placebo recipients. For example, a new prescription for an anticoagulant after atrial fibrillation is diagnosed should prompt communication between the cardiology and Alzheimer’s treatment teams before the next home dose. Patients should not stop a prescribed blood thinner on their own, but neither should the neurology team remain unaware of the change.
Missed Doses and Changes Back to IV Treatment
If a weekly subcutaneous dose is missed, current instructions allow it to be administered as soon as possible within six days of the missed dose. The next injection is then given on the original scheduled day. If more than six days have passed, the family should contact the prescribing team instead of improvising a new schedule or administering two doses close together.
A patient can also switch back to IV treatment. During the starting regimen, the first IV dose should be given at least two weeks—but no more than three weeks—after the last subcutaneous dose. During maintenance, the first IV dose is given one week after the last subcutaneous dose. These intervals differ, so the infusion center needs to know whether the patient was using the 500-milligram starting regimen or the 360-milligram maintenance regimen.
Frequently Asked Questions
Can a patient switch to Leqembi injections before completing 18 months of IV treatment?
Yes. Current U.S. prescribing information allows switching from IV to subcutaneous administration during the starting regimen. The first subcutaneous dose is given one week after the last IV dose, as directed by the prescriber.
Can the first Leqembi injection be given at home?
Treatment with Leqembi IQLIK begins under healthcare-provider guidance and supervision. The provider must give direct guidance for at least two consecutive subcutaneous doses and determine that the patient or caregiver can administer the drug appropriately before home use.
Is the at-home starting dose one injection?
No. The 500-milligram weekly starting dose requires two 250-milligram injections. After 18 months, the subcutaneous maintenance dose is 360 milligrams once weekly using one autoinjector.
Do patients still need MRIs after switching?
Yes. Home administration does not replace MRI monitoring or clinical follow-up. Scheduled imaging and additional evaluation for possible ARIA remain part of treatment.
Can a caregiver give Leqembi IQLIK?
Yes, after appropriate training and the prescriber’s assessment. A caregiver may inject the abdomen, thigh, or back of the upper arm, while patients administering their own dose use the abdomen or thigh.
Does insurance automatically cover the injection because it is FDA-approved?
No. Coverage, prior authorization, pharmacy distribution, and out-of-pocket costs can differ between an infused medical benefit and a self-administered drug benefit. The prescribing office and insurer should verify coverage before an infusion appointment is canceled.
